Showing results (851-860 of 1,190) with videos related to

Sort By:
Pageof 119
The Lancet. Haematology|July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialTapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
Blood|May 23, 2008
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemiaGuillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, et al.
Cancer|March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulationDaniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
The Lancet. Microbe|February 26, 2026
Global perspective on gaps in fungal diagnostics in low-resource settings: WHO landscape analysis and research priorities for invasive fungal diseasesMaurine Murtagh, P Lewis White, Juan Luis Rodriguez-Tudela, et al.
Neuro-Oncology|June 23, 2012
EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasionArend H Sikkema, Wilfred F A den Dunnen, Esther Hulleman, et al.
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Blood Advances|January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisPrajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
American Journal of Hematology|July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
Blood Neoplasia|September 8, 2025
Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 studyMrinal M Patnaik, Haris Ali, Eunice S Wang, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Pageof 119